Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

High Risk Prostate Cancer × apalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 78 Neoplasm Metastasis 4 Prostatic Neoplasms, Castration-Resistant 3 Prostatic Diseases 2 Non-metastatic Castration-resistant Prostate Cancer 2 Genital Diseases, Male 2 Urogenital Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sleep Initiation and Maintenance Disorders 1 Salivary Gland Neoplasms 1 Prostate Cancer With ≤10 Bone Metastases 1 Prostate Cancer Metastatic Disease 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Patient Preference 1 Non-Muscle Invasive Bladder Urothelial Carcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Low Risk Prostate Cancer 1 High-Risk and Oligometastatic Prostate Cancer 1 High Risk Prostate Cancer 1

Interventions

apalutamide 1 Receptors, Androgen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06758882 2025-01-06

STAPLE

A.O.U. Città della Salute e della Scienza

Phase 2 Recruiting

High Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡